, several studies have shown that the De Ritis (aspartate transaminase/alanine transaminase) ratio can be a useful prognostic biomarker in patients with certain types of malignant tumors. However, the prognostic value of the De Ritis ratio in patients with upper tract urothelial carcinoma remains largely unknown. The aim of the present study was to evaluate the prognostic significance of the De Ritis ratio in patients with upper urinary tract urothelial carcinoma after radical nephroureterectomy (RNU). METHODS: One thousand forty-nine patients who underwent RNU at eight institutions from 2004 to 2015 were retrospectively reviewed. The effect of the De Ritis ratio and conventional clinicopathological parameters were analyzed. Survival analysis was performed using the Kaplan-Meier method and log-rank test. Multivariable analysis was performed using the Cox proportional hazard regression model. Cutoff values of the De Ritis ratio were calculated using a receiver operating characteristic curve (ROC).
INTRODUCTION AND OBJECTIVES: Recently
, several studies have shown that the De Ritis (aspartate transaminase/alanine transaminase) ratio can be a useful prognostic biomarker in patients with certain types of malignant tumors. However, the prognostic value of the De Ritis ratio in patients with upper tract urothelial carcinoma remains largely unknown. The aim of the present study was to evaluate the prognostic significance of the De Ritis ratio in patients with upper urinary tract urothelial carcinoma after radical nephroureterectomy (RNU). METHODS: One thousand forty-nine patients who underwent RNU at eight institutions from 2004 to 2015 were retrospectively reviewed. The effect of the De Ritis ratio and conventional clinicopathological parameters were analyzed. Survival analysis was performed using the Kaplan-Meier method and log-rank test. Multivariable analysis was performed using the Cox proportional hazard regression model. Cutoff values of the De Ritis ratio were calculated using a receiver operating characteristic curve (ROC).
RESULTS: According to the ROC curve, the cutoff value for overall death was 1.6 (p¼0.002). The cancer-specific survival (CSS) and overall survival (OS) were significantly shorter for patients with a high De Ritis ratio (>1.6). Results of multivariable analysis identified an increased De Ritis ratio (>1.6) as independently related to worse CSS (hazard ratio [HR] 2.49, 95% confidence interval [CI] 1.70-3.64; p¼0.001) and OS (HR 1.84, 95% CI 1.34-2.52; p¼0.001).
CONCLUSIONS: Our results suggest that the De Ritis ratio can be a significant predictor of oncological outcomes in patients with upper urinary tract urothelial carcinoma after surgery. Recent studies have argued that the actual metastatic rate of eAML is very low. This retrospective study aims to analyze the aggressive behavior rate and describe the vast clinicopathalogical variety of eAML.
Source of
METHODS: In Chang Gung Memorial Hospital, Taiwan, a total of 887 patients were diagnosed with AML from 2001 to 2016 according to the healthcare information system archive, including 21 cases of renal eAML. All of the cases were diagnosed according to tissue proof and immunohistochemical studies. The images, pathology and medical records of these 21 eAML cases were reviewed and summarized.
RESULTS: In these 21 eAML cases, the average age was 43.1 (ranges from 18 to 64), including 6 males and 15 females. All 21 cases are not associated with tuberous sclerosis complex. The longest diameter of the tumors ranges from 1.3 to 20 centimeters (average 9.8 cm). Three of these cases had multiple tumors (single eAML and single AML coexist on the left kidney, clear cell renal cell carcinoma on the right and single eAML on the left, multiple AML on e872 THE JOURNAL OF UROLOGY â Vol. 197, No. 4S, Supplement, Sunday, May 14, 2017 bilateral kidneys with single eAML on the left). Only one patient suffered from spontaneous haemorrhage. Two cases developed distant metastasis: one had nodules over bilateral lungs and left anterior mediastinum; the other had recurrence over liver and retroperitoneum one year after surgical intervention. Three cases had venous thrombus (two in renal vein and one in inferior vena cava) and received thrombectomy. All 21 cases received surgical intervention: 13 radical nephrectomy, 7 partial nephrectomy, one was found with retroperitoneal eAML arising from renal capsule thus undergone tumor excision without kidney involvement. The follow up period ranges from 1 to 143 months (average 51 months). Only 2 cases died from unrelated cause. CONCLUSIONS: In our study, the rate of aggressive behavior is 24% (2 distant metastasis and 3 venous invasion in the 21 cases). Some noticeable accompanying characteristics including haemorrhage, coexisting with AML, coexisting with renal cell carcinoma are also seen in this series. The incidence of renal vein and inferior vena cava thrombus formation in our series is high (3 out of 21), therefore, detailed preoperative image evaluation is necessary. 0% of all RCCs. This subtype has been predominantly studied in single-institution datasets and little is known about treatment patterns and outcomes. We sought to utilize a large, population-level database to assess survival outcomes for this rare disease.
METHODS: The national cancer database (NCDB) was queried for all cases of CDRCC and clear cell RCC (CCRCC) from 2004-13. After patients with other cancer diagnoses were removed, the analytic cohort was composed of 202,263 CCRCC and 577 CDRCC cases. Kaplan-Meier and cox proportional hazards analysis were employed to model survival.
RESULTS: Compared to CCRCC, patients with CDRCC presented with higher grade and stage, node-positive and metastatic disease (70.7% versus 30.0% with metastasis). Overall median survival for CDRCC was 13.2 months (95% CI 11.0-15.5) compared to the 122.5-month (121.0-123.9) for CCRCC. On multivariate analysis of the CDRCC cohort, increasing T stage, high-grade disease and metastasis were predictors of mortality. Of 184 patients with metastatic CDRCC, 113 underwent cytoreductive nephrectomy (CNx) while the rest were treated with multimodal therapy (MMT) alone or observed. Survival outcomes were improved in patients who received both CNx with MMT compared to surgery alone (HR 0.51, 95% CI 0.32-0.79) or MMT alone (HR 0.57, 95% CI 0.37-0.89) on multivariate analysis.
CONCLUSIONS: Collecting (Bellini) Duct carcinoma is an aggressive subtype of RCC. Median survival is 13 months after diagnosis, drastically lower than for CCRCC. Over 70% of patients are diagnosed with metastatic disease. Multimodal therapy in addition to cytoreductive nephrectomy is associated with a survival benefit over single mode therapy. 

INTRODUCTION AND OBJECTIVES: Stage II Renal Cell
Carcinoma (RCC) is characterized by varied oncological outcomes, as the risk of progression and recurrence can vary widely. We analyzed clinical and pathological risk factors associated with oncological outcomes in a multicenter, international cohort.
METHODS: Retrospective multicenter analysis of patients who underwent surgical excision of clinically localized stage 2 (T2) renal mass from 1987-2015. Patients with tumors amenable to nephronsparing surgery, baseline chronic kidney disease, or bilateral renal masses were provided an option for partial nephrectomy (PN), otherwise radical nephrectomy (RN) was performed. Lymphadenectomy (LND) was performed when clinically indicated. Primary endpoint was Recurrence Free Survival (RFS). Secondary outcome was overall survival (OS). Kaplan-Meier (KM) log-rank test and multivariable analysis (MVA) for factors related to RFS and OS were performed.
RESULTS: 1328 patients were analyzed (mean age 59.2 years, median follow up 62.7 months, 66.4% male/33.6% female, 20% PN/ 80% RN). Overall recurrence rate was 22.3%. MVA for factors associated with recurrence was significant for RN (OR 4.68, p¼0.010), positive margin (OR 34.19, p¼0 .012), tumor grade 3/4 (OR 2.35, p¼0.001), and lymphovascular invasion (LVI, OR 2.03, p¼0.018). MVA for tumor related factors associated with worsened OS was significant only for RN (OR 4.16, p¼0.001) . KM analysis revealed 5 year RFS of 78.7% for LVI negative and 49.9% for LVI positive patients (p<0.001), as well as a 5 year RFS of 81.8% for tumor grade 1/2 and 62.1% for tumor grade 3/4 (p<0.001, figure) .
CONCLUSIONS: For Stage II RCC, LVI and tumor grade 3/4 are independently associated with increased risk of recurrence. Stage II RCC patients with these pathological findings represent a high risk subgroup that requires close follow up and has implications for clinical trial design.
